BWX Technologies Already Builds Reactors for the Navy. Why Is It Still the Cheapest Nuclear Stock?

BWX Technologies projects double-digit revenue and EPS growth, highlighted by Q2 revenue of $901.6M (+18% YoY) and EPS of $1.07 (+5% YoY). The company signed $1.4B in new U.S. Navy Nuclear Propulsion Program contracts, taking backlog to over $8.6B, and raised full-year guidance to $3.8B revenue (+61.7%) and non-GAAP EPS of $4.70-$4.80 (+18% at the midpoint). Commercial momentum is accelerating with Q2 commercial revenue up to $303M (+72% YoY) and management targeting ~45% growth in commercial sales for 2024 driven by recent acquisitions.

Analysis

BWXT is best viewed as a regulated-adjacent defense compounder, not a typical nuclear beta trade. The real edge is not the growth rate itself but the combination of sole-source positioning, long-dated contract visibility, and a customer that values schedule certainty over price — that tends to support cash conversion even when broader defense multiples compress. In other words, the stock’s upside is more about de-risked execution and gradual margin accretion than a sudden re-rating.

The second-order effect is that BWXT is a bottleneck beneficiary of any acceleration in naval modernization and nuclear-adjacent supply chains. That helps BWXT more than broad uranium miners: CCJ/UEC get only indirect demand lift unless enriched-fuel scarcity becomes a real constraint, while SMR/OKLO are exposed to the fact that commercialization depends on specialized fabrication and fuel infrastructure that BWXT already controls. By contrast, CEG/DUK should be treated as sentiment proxies for the nuclear theme rather than direct earnings beneficiaries.

Near term, the key catalyst is not macro but contract conversion and guidance follow-through over the next 1-3 quarters; the stock can underperform if backlog turns out to be low-margin or acquisition-driven rather than organically accretive. The main falsifier is any sign of Navy procurement delay, program cost inflation, or commercial margin disappointment in the next earnings cycle. Contrarian view: the market may be underestimating BWXT’s quality versus other nuclear names, but it may still be overestimating how quickly monopoly status translates into incremental ROIC.

Key Decisions for Investors

• Long BWXT on weakness over the next 1-3 months; best entry is on any post-earnings or defense-sector pullback. Base case is modest multiple expansion as backlog converts to cash flow; thesis breaks if FY guidance is trimmed or Navy awards stall.
• Pair trade: long BWXT / short SMR for 3-6 months. This expresses quality vs. story — BWXT has visibility and cash generation, while SMR remains more dependent on future regulatory and commercialization milestones. Cover if SMR wins a material utility/DOE catalyst or BWXT misses margin expansion.
• Relative value: long BWXT / short OKLO as a cleaner hedge on nuclear enthusiasm. BWXT monetizes the supply chain today; OKLO needs a timeline acceleration to justify current enthusiasm. Risk is a sharp policy-positive catalyst for advanced reactors.
• Do not chase CCJ or UEC solely on this print; wait for evidence that enriched-fuel constraints are widening beyond naval applications. If HALEU/fuel fabrication pricing starts to inflect, then revisit as a 6-12 month thematic long.